S&P 500   3,302.70 (+0.66%)
DOW   27,218.99 (+0.26%)
QQQ   271.27 (+1.41%)
AAPL   110.86 (+0.71%)
MSFT   206.20 (+1.81%)
FB   253.05 (+1.97%)
GOOGL   1,452.86 (+1.59%)
AMZN   3,107.50 (+4.97%)
NVDA   499.48 (-0.24%)
TSLA   428.85 (-4.57%)
BABA   273.28 (-0.20%)
CGC   16.00 (+1.65%)
GE   6.23 (-1.89%)
MU   49.51 (+0.73%)
AMD   77.09 (-1.09%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.22 (+14.24%)
GILD   63.59 (-0.97%)
NFLX   489.04 (+0.35%)
DIS   126.90 (+1.19%)
BAC   23.89 (-2.37%)
BA   156.63 (+0.18%)
S&P 500   3,302.70 (+0.66%)
DOW   27,218.99 (+0.26%)
QQQ   271.27 (+1.41%)
AAPL   110.86 (+0.71%)
MSFT   206.20 (+1.81%)
FB   253.05 (+1.97%)
GOOGL   1,452.86 (+1.59%)
AMZN   3,107.50 (+4.97%)
NVDA   499.48 (-0.24%)
TSLA   428.85 (-4.57%)
BABA   273.28 (-0.20%)
CGC   16.00 (+1.65%)
GE   6.23 (-1.89%)
MU   49.51 (+0.73%)
AMD   77.09 (-1.09%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.22 (+14.24%)
GILD   63.59 (-0.97%)
NFLX   489.04 (+0.35%)
DIS   126.90 (+1.19%)
BAC   23.89 (-2.37%)
BA   156.63 (+0.18%)
S&P 500   3,302.70 (+0.66%)
DOW   27,218.99 (+0.26%)
QQQ   271.27 (+1.41%)
AAPL   110.86 (+0.71%)
MSFT   206.20 (+1.81%)
FB   253.05 (+1.97%)
GOOGL   1,452.86 (+1.59%)
AMZN   3,107.50 (+4.97%)
NVDA   499.48 (-0.24%)
TSLA   428.85 (-4.57%)
BABA   273.28 (-0.20%)
CGC   16.00 (+1.65%)
GE   6.23 (-1.89%)
MU   49.51 (+0.73%)
AMD   77.09 (-1.09%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.22 (+14.24%)
GILD   63.59 (-0.97%)
NFLX   489.04 (+0.35%)
DIS   126.90 (+1.19%)
BAC   23.89 (-2.37%)
BA   156.63 (+0.18%)
S&P 500   3,302.70 (+0.66%)
DOW   27,218.99 (+0.26%)
QQQ   271.27 (+1.41%)
AAPL   110.86 (+0.71%)
MSFT   206.20 (+1.81%)
FB   253.05 (+1.97%)
GOOGL   1,452.86 (+1.59%)
AMZN   3,107.50 (+4.97%)
NVDA   499.48 (-0.24%)
TSLA   428.85 (-4.57%)
BABA   273.28 (-0.20%)
CGC   16.00 (+1.65%)
GE   6.23 (-1.89%)
MU   49.51 (+0.73%)
AMD   77.09 (-1.09%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.22 (+14.24%)
GILD   63.59 (-0.97%)
NFLX   489.04 (+0.35%)
DIS   126.90 (+1.19%)
BAC   23.89 (-2.37%)
BA   156.63 (+0.18%)
Log in
NYSE:RDY

Dr.Reddy's Laboratories News Headlines

$70.00
+0.22 (+0.32 %)
(As of 09/22/2020 02:38 PM ET)
Add
Compare
Today's Range
$69.60
Now: $70.00
$70.08
50-Day Range
$58.17
MA: $61.06
$72.41
52-Week Range
$33.33
Now: $70.00
$73.50
Volume4,791 shs
Average Volume202,240 shs
Market Capitalization$11.60 billion
P/E Ratio46.05
Dividend Yield0.37%
Beta0.51

Headlines

Dr.Reddy's Laboratories (NYSE RDY) News Headlines Today

Source:
DateHeadline
Dr.Reddys Laboratories (NYSE:RDY) Rating Increased to Hold at ValuEngineDr.Reddy's Laboratories (NYSE:RDY) Rating Increased to Hold at ValuEngine
marketbeat.com - August 4 at 12:52 AM
India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks - execIndia trials for Russia's 'Sputnik-V' vaccine could start in next few weeks - exec
finance.yahoo.com - September 22 at 8:08 AM
Dr.Reddys Laboratories (NYSE:RDY) Shares Gap Up to $66.55Dr.Reddy's Laboratories (NYSE:RDY) Shares Gap Up to $66.55
americanbankingnews.com - September 18 at 11:15 AM
Dr.Reddys Laboratories (NYSE:RDY) Lifted to Buy at BofA SecuritiesDr.Reddy's Laboratories (NYSE:RDY) Lifted to Buy at BofA Securities
americanbankingnews.com - September 18 at 10:17 AM
Dr.Reddys Laboratories (NYSE:RDY) Raised to "Hold" at InvestecDr.Reddy's Laboratories (NYSE:RDY) Raised to "Hold" at Investec
americanbankingnews.com - September 18 at 8:58 AM
Dr.Reddys Laboratories (NYSE:RDY) Stock Price Up 6.3%Dr.Reddy's Laboratories (NYSE:RDY) Stock Price Up 6.3%
americanbankingnews.com - September 17 at 9:04 PM
Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb CompanyDr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company
finance.yahoo.com - September 17 at 8:34 AM
Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. MarketDr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market
finance.yahoo.com - September 17 at 3:34 AM
India Pharma Inks Supply, Clinical Trials Pact For Russia's Sputnik Coronavirus VaccineIndia Pharma Inks Supply, Clinical Trials Pact For Russia's Sputnik Coronavirus Vaccine
finance.yahoo.com - September 16 at 12:31 PM
Dr.Reddys Laboratories (NYSE:RDY) Sets New 52-Week High at $65.02Dr.Reddy's Laboratories (NYSE:RDY) Sets New 52-Week High at $65.02
americanbankingnews.com - September 16 at 11:11 AM
RDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to IndiaRDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India
finance.yahoo.com - September 16 at 7:30 AM
Russia to provide Indian drug company Dr. Reddy's with 100 million doses of its COVID-19 vaccineRussia to provide Indian drug company Dr. Reddy's with 100 million doses of its COVID-19 vaccine
finance.yahoo.com - September 16 at 7:30 AM
Analyst Report: Dr. Reddy's Laboratories LimitedAnalyst Report: Dr. Reddy's Laboratories Limited
finance.yahoo.com - September 14 at 5:47 PM
Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. MarketDr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
finance.yahoo.com - September 9 at 4:58 AM
Dr. Reddys Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market
businesswire.com - September 7 at 2:59 PM
Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market
finance.yahoo.com - September 7 at 9:53 AM
Dr. Reddys Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. MarketDr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market
finance.yahoo.com - September 3 at 3:54 AM
Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. MarketDr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market
finance.yahoo.com - September 3 at 3:54 AM
Dr. Reddys Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. MarketDr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market
finance.yahoo.com - August 27 at 7:29 AM
Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. MarketDr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market
finance.yahoo.com - August 27 at 7:29 AM
Dr. Reddys Laboratories announces the launch of AVIGAN ® (Favipiravir) in IndiaDr. Reddy's Laboratories announces the launch of AVIGAN ® (Favipiravir) in India
businesswire.com - August 19 at 9:38 AM
Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in IndiaDr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India
finance.yahoo.com - August 19 at 9:38 AM
Why the Boom in India’s Pharmaceutical Stocks May FadeWhy the Boom in India’s Pharmaceutical Stocks May Fade
finance.yahoo.com - August 13 at 6:53 PM
Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. MarketDr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market
finance.yahoo.com - August 11 at 12:56 AM
Dr. Reddy’s Q1 FY21 Financial ResultsDr. Reddy’s Q1 FY21 Financial Results
finance.yahoo.com - July 29 at 8:06 AM
Top 5 Indian Stocks to Invest InTop 5 Indian Stocks to Invest In
stocknews.com - July 27 at 1:55 PM
Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.
finance.yahoo.com - July 27 at 11:00 AM
Dr Reddy’s Scoops FDA Nod For Breakthrough Head Lice TreatmentDr Reddy’s Scoops FDA Nod For Breakthrough Head Lice Treatment
finance.yahoo.com - July 27 at 11:00 AM
Dr. Reddy's to release Q1 FY 21 results on July 29th, 2020Dr. Reddy's to release Q1 FY 21 results on July 29th, 2020
finance.yahoo.com - July 20 at 9:15 AM
Dr. Reddys Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. MarketDr. Reddy's Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market
www.businesswire.com - July 14 at 9:29 AM
Dr. Reddy's Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. MarketDr. Reddy's Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market
finance.yahoo.com - July 14 at 9:29 AM
India's Cipla set to undercut rivals with generic remdesivir -sourcesIndia's Cipla set to undercut rivals with generic remdesivir -sources
finance.yahoo.com - July 8 at 9:14 AM
Hedge Funds Are Selling Dr. Reddy’s Laboratories Limited (RDY)Hedge Funds Are Selling Dr. Reddy’s Laboratories Limited (RDY)
finance.yahoo.com - July 5 at 6:38 PM
Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19
finance.yahoo.com - July 1 at 9:48 AM
Dr. Reddys Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. MarketDr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market
finance.yahoo.com - June 19 at 7:57 AM
Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. MarketDr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market
finance.yahoo.com - June 19 at 7:57 AM
Dr. Reddys Laboratories Limited announces filing of Annual Report on Form 20-FDr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F
www.benzinga.com - June 17 at 1:01 PM
Dr. Reddys Laboratories enters into a Licensing Agreement with Gilead Sciences for RemdesivirDr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir
finance.yahoo.com - June 13 at 8:15 AM
Dr. Reddy’s Laboratories Completes the Acquisition of Select Business Divisions of WockhardtDr. Reddy’s Laboratories Completes the Acquisition of Select Business Divisions of Wockhardt
finance.yahoo.com - June 10 at 9:23 AM
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues BeatDr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
finance.yahoo.com - May 21 at 1:09 PM
Dr. Reddys Laboratories Ltd. to Host Earnings CallDr. Reddy's Laboratories Ltd. to Host Earnings Call
finance.yahoo.com - May 20 at 8:11 PM
Dr. Reddy’s Q4 & FY20 Financial ResultsDr. Reddy’s Q4 & FY20 Financial Results
finance.yahoo.com - May 20 at 10:09 AM
Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020
finance.yahoo.com - May 7 at 7:28 AM
Dr. Reddys Laboratories Received Approval for Their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.Dr. Reddy's Laboratories Received Approval for Their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.
finance.yahoo.com - May 7 at 2:27 AM
Dr. Reddy's Laboratories Received Approval for Their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.Dr. Reddy's Laboratories Received Approval for Their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.
finance.yahoo.com - May 7 at 2:27 AM
Dr. Reddys Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market
finance.yahoo.com - May 6 at 7:48 AM
Dr. Reddys Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. Market
www.businesswire.com - April 27 at 9:11 AM
Dr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. Market
finance.yahoo.com - April 27 at 9:11 AM
Dr. Reddys Laboratories Announces the Launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. Market
www.bloomberg.com - April 25 at 11:46 PM
Bull of the Day: Dr. Reddy's Laboratories (RDY)Bull of the Day: Dr. Reddy's Laboratories (RDY)
finance.yahoo.com - April 24 at 2:04 PM
Dr. Reddys Laboratories Announces the Launch of an Authorized Generic Version of NitroDur® (nitroglycerin) Transdermal Infusion System in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of an Authorized Generic Version of NitroDur® (nitroglycerin) Transdermal Infusion System in the U.S. Market
www.businesswire.com - April 14 at 8:33 AM
This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.